Vaccines
In 2007, Novartis was the first company to have a licensed, commercially produced and marketed cell culture-based vaccine to prevent influenza. We operate a cell culture-based manufacturing plant in Marburg, Germany. And in November 2009, Novartis inaugurated the US's first ever large-scale flu cell culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina.
Novartis utilizes both egg and cell culture technology to manufacture vaccines.
Cell culture-based
General - Videos
Shots of an employee in protective clothing with cell culture equipment at -180° C (0:17)
General - Photos
Holly Springs
Photo
Video
Brochure
Overview of the Novartis flu cell culture vaccine and adjuvant production facility in Holly Springs, North Carolina.
Egg-based
Photo
Video
MF59 Adjuvant
Photos
Video
You may use the multimedia material provided in this section for commercial purposes only in relation to Novartis. These images must not be modified in any way and each item must have the copyright acknowledgement of Novartis AG (© Novartis AG).
